[News Brief] DKSH Partners with Lilly in Hong Kong and Macau
DKSH Business Unit Healthcare has entered into a distribution and promotion agreement with Eli Lilly Export S.A. to sell, promote…
Press Release
[News Brief] CanSinoBIO Receives Argentine Approval for Meningococcal Vaccine
CanSino Biologics Inc. has received a drug registration certificate from Argentina’s Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT)…
[News Brief] Anixa Biosciences Secures South Korean Patent for Breast Cancer Vaccine
Anixa Biosciences has announced that the Korean Ministry of Intellectual Property has granted a composition-of-matter patent for its breast cancer…
[News Brief] Santé Accel Singapore Launches Healthcare Venture-Building Platform
[News Brief] Santé Accel Singapore Launches Healthcare Venture-Building Platform Santé Accel Singapore, a healthcare venture-building platform, has been launched to…
[News Brief] NeuroSense Reports Phase 2 Biomarker Findings for PrimeC
[News Brief] NeuroSense Reports Phase 2 Biomarker Findings for PrimeC NeuroSense Therapeutics has reported biomarker findings from its Phase 2…
[News Brief] Nippon Shinyaku Signs Option Agreement with Elixirgen
Nippon Shinyaku has entered into an option agreement with Elixirgen Therapeutics under which it may obtain exclusive worldwide rights to…
[News Brief] Zydus Lifesciences and Sunshine Healthcare Form Sri Lanka Joint Venture
Zydus Lifesciences and Sunshine Healthcare have announced a joint venture to establish a pharmaceutical manufacturing facility in Sri Lanka. This…
[News Brief] Abbisko Expands R&D Collaboration with Eli Lilly
Abbisko Therapeutics has entered into a strategic research collaboration and licence agreement with Eli Lilly and Company to discover and…
[News Brief] Haisco Licenses Drug Candidates to Nuvectis
Haisco Pharmaceutical Group has entered into an exclusive licensing agreement with US-based biotechnology company Nuvectis for two internally developed clinical-stage…
[News Brief] CeleCor Completes FDA Application for Heart Attack Drug
CeleCor Therapeutics has completed its New Drug Application (NDA) submission to the US Food and Drug Administration (FDA) for investigational…